Natera, Inc. (NTRA)
Natera, Inc. (NTRA) from its SEC filings: 2025 revenue $2.3 billion (+36% vs the year before), net margin -9%, free cash flow $109.1 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Services-Medical Laboratories |
| Revenue (2025) | $2.3 billion |
| Revenue growth | +36% |
| Net income | -$208.2 million |
| Net margin | -9.0% |
| Free cash flow | $109.1 million |
| Diluted EPS | $-1.52 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +38% |
| Cash | $466.0 million |
| Long-term debt | $282.9 million |
| Share count, 1 year | +5% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.